Pacira Pharmaceuticals (NASDAQ:PCRX)

Novel delivery mechanism for generic bipuvicaine that enables 72-hour post-surgery pain relief with a single shot, minimizing the need for opioids. Zero competition and huge target market. Potential to double in 18-24 months.

Their single product, an injectable, long lasting pain reliever, is going to revolutionize post surgical patient care.

Driven up too high on excitement over one drug--which itself will not bring these guys into profitability.

This drug will enable providers to send their patients home with minimal narcotics, providing days of minimal post-operative pain, without the untoward complications.

The commercial success of Exparel is a tough call to make. Intuitively, the drug seems to be filling an important niche in post-operative pain management. But empirical evidence tells us that launches of new drugs are usually slow, and expecially in the pain sector failures have been abundant. Now that the share price has made a move upward, I'm going to bet that the stock declines as speculators abandon their positions ahead of initial sales data.